MARKET

GMAB

GMAB

Genmab
NASDAQ

Real-time Quotes | Nasdaq Last Sale

21.19
+0.71
+3.47%
After Hours: 21.00 -0.19 -0.90% 18:24 03/31 EDT
OPEN
20.32
PREV CLOSE
20.48
HIGH
21.64
LOW
20.09
VOLUME
1.25M
TURNOVER
--
52 WEEK HIGH
25.42
52 WEEK LOW
16.24
MARKET CAP
13.77B
P/E (TTM)
41.48
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average GMAB stock price target is 28.60 with a high estimate of 31.00 and a low estimate of 27.00.

EPS

GMAB News

More
  • Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for on-demand viewing
  • PR Newswire · 5d ago
  • Hedge Funds Have Never Been This Bullish On Genmab A/S (GMAB)
  • Insider Monkey · 03/17 20:51
  • 10 International ADR Companies That Are Conducting Virtual Investor Presentations This Week
  • Benzinga · 03/17 16:30
  • International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on March 18th and 19th, 2020
  • PR Newswire · 03/16 13:35

Industry

Biotechnology & Medical Research
-0.49%
Pharmaceuticals & Medical Research
-0.25%

Hot Stocks

Symbol
Price
%Change

About GMAB

Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer, with a focus on solid tumors and hematological cancer. The Company has two approved antibodies: DARZALEX (daratumumab) and Arzerra (ofatumumab). DARZALEX is approved in combination with other standard therapies in frontline multiple myeloma, relapsed/refractory multiple myeloma and as a monotherapy for heavily pretreated or double-refractory multiple myeloma. It is marketed in the United States (U.S.), Europe and Japan. Arzerra is approved in certain territories for various chronic lymphocytic leukemia (CLL) indications and is marketed in the U.S. and Japan. The Company also develops a broad clinical and pre-clinical product pipeline, both own and partnered, and owns four proprietary antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
More

Webull offers kinds of Genmab A/S stock information, including NASDAQ:GMAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GMAB stock news, and many more online research tools to help you make informed decisions.